Moderate To Severe Glabellar Lines clinical trials

Explore recruiting moderate to severe glabellar lines clinical trials.

Recruiting moderate to severe glabellar lines studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Moderate To Severe Glabellar Lines trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A phase III, multicentre, double-blind, randomised, placebo-controlled and open-label study to evaluate the efficacy and safety of a single dose of IPN10200 in the improvement of moderate to severe glabellar lines in adult participants, and to evaluate the long-term efficacy and safety of repeat doses of IPN10200 in the same indication.

France, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

Moderate To Severe Glabellar Lines trials by city

Moderate To Severe Glabellar Lines in Toronto Moderate To Severe Glabellar Lines in Vancouver Moderate To Severe Glabellar Lines in Montreal Moderate To Severe Glabellar Lines in Calgary Moderate To Severe Glabellar Lines in Edmonton Moderate To Severe Glabellar Lines in Ottawa Moderate To Severe Glabellar Lines in Winnipeg Moderate To Severe Glabellar Lines in Quebec City Moderate To Severe Glabellar Lines in Hamilton Moderate To Severe Glabellar Lines in Kitchener Moderate To Severe Glabellar Lines in London Moderate To Severe Glabellar Lines in Halifax Moderate To Severe Glabellar Lines in New York Moderate To Severe Glabellar Lines in Los Angeles Moderate To Severe Glabellar Lines in Chicago Moderate To Severe Glabellar Lines in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease